Virios Therapeutics Inc (VIRI) News

TROY, Mich., March 17, 2025 (GLOBE NEWSWIRE) -- Viper Networks (OTCPK: VPER) released its Annual Report today, showing strong revenue growth, substantially improved cash flow, and positive EBITDA (non-GAAP) in the 4th quarter of 2024.
Substantial milestones for the year include:
• The company closed on the acquisition of the telecommunications assets of Hammer Fiber Optics Holdings Corp – 0Wire Communications, LLC (formerly 1stPoint Communications, LLC) and its subsidiaries and Endstream Communications, LLC – in exchange for 2,500,000 shares of HMMR common stock. The HMMR common stock was obtained in a Share Exchange Agreement with two related parties in exchange for the company’s Series B preferred stock.
• During the year the company completed the deployment of 108 smart poles and their Apollo smart lights in the capital city of Colombo, Sri Lanka. The project was a pilot for future projects which are currently in the design phase.
• The company progressed in its proposed pilot project to deploy smart poles in the Chicago greater metro area, and expects to finalize the project in the coming quarters.
• The company also progressed in its deployment in the Eastern Caribbean, with the first deployment expected in the third quarter of 2025.
• The Board of Directors approved the conversion of $419,340 in notes payable to related parties to Series B preferred stock and the conversion of $225,000 in accrued salaries of related parties to Series B preferred stock, substantially improving the company’s balance sheet.
• All responsibility for the accounting and financial operations of the company have been assumed by the accounting and management staff of 0Wire Communications. The management and operations of the company improved substantially, with the addition of a new Chief Executive Officer, Chief Administrative Officer and Secretary along with several other key senior management positions.
• The company began its strategic rebranding effort. 0Wire was selected because of its alignment with the company’s Everything Wireless: Telecommunications+Energy strategy.

VIRA to DWTX, 10/9/2024: 1:25 reverse split

VIRI........................https://stockcharts.com/h-sc/ui?s=VIRI&p=W&b=5&g=0&id=p86431144783

DWTX new merger symbol .16 + 15%

08:39 AM EDT, 10/07/2024 (MT Newswires) -- Virios Therapeutics (VIRI) said Monday it has entered into a definitive share exchange agreement to merge with Wex Pharmaceuticals, another subsidiary of CK Life Sciences International, in an all-stock transaction.

Virios is a wholly owned subsidiary of CK Life Sciences International, and its indirect parent is Sealbond Ltd., the sole stockholder of Wex, and an indirect subsidiary of CKLS.

The fully diluted equity value for the combined entity is estimated at $105 million, excluding transaction fees.

Virios will change its name to Dogwood Therapeutics, effective Wednesday. The company's common stock will cease trading under the ticker symbol VIRI and will begin trading on the Nasdaq Capital Market under the ticker symbol "DWTX."

In connection to the merger, Virios is announcing a 25-for-1 reverse stock split, also effective Wednesday, resulting in outstanding shares of common stock of 1.1 million shares prior to the issuance of shares following the share exchange agreement. The split will automatically result in the conversion of 25 common shares of Virios into one new share of Dogwood. After the reverse stock split, Sealbond will hold around 94% ownership, while pre-merger Virios stockholders will retain about 6% ownership.

In addition to the merger, the company said it is raising $19.5 million in debt financing from a CK Life Sciences International affiliate in two tranches with $16.5 million funding at closing and an additional $3 million funded in Q1.

The financing for Dogwood will focus on the clinical development of three major assets: Halneuron for chemotherapy-induced neuropathic pain, IMC-1 for fibromyalgia, and IMC-2 for long-COVID treatment.

Price: 0.1771, Change: +0.01, Percent Change: +2.97

FYI it’s still summer lol 4 more days …

Just one month away from a Reverse split, Thank you Mr Greg Duncan you are a mastermind in this. What happened to the destined partnership for Phase 3 Fibromyalgia, even given a commencing date of summer 2024- I guess it all lies, no one should trust this moron

Why greg Duncan stretching a lot of news such as partnership of fibromyalgia and Long covid data? feels like reverse split is imminent

VIRI...1947...Back in here on the Double Bottom...🥳

Exactly, my biggest fear is no volume and the shorts push it down

I hope you’re right bud! We’ll all know before the middle of October. VIRI LONG💰

No RS

Happy Monday to all. What's happening with VIRI? feels like RS is happening sooner than later

I hope so. been holding 150 thousand shares, total gamble

I believe we move above $1/share without a RS. VIRI LONG💰

News expected October. Compliance deadline is 28th October. Do you reckon we avoid a reverse split ?

VIRI NEWS!!

https://ir.virios.com/news/press-releases/detail/120/virios-therapeutics-announces-completion-of-enrollment-in

Nice $37,000 BID for a Friday morning😉 VIRI LONG💰

What?🤣😆 VIRI LONG💰💰

very disappointed atm :(

if it keeps dipping, i may get back in.

Multiple dollars could come quickly here folks!! VIRI LONG💰

I’m sure you will be fine😎 They drop some IMC-1 phase 3 partnership news, and we’re off to the races!!💰

looks like i should have waited, lol

hi cj! i just grabbed some pre market.

Gotta be!! Over 7 million traded now, and hit .39 earlier.😎

News coming????

6 million shares already traded premarket!! Let’s go VIRI😎💰

$trong AH's 💲💲💲

VIRI up over 22%. Partnership news could be dropping folks!!

Up 10% with some nice ASK slapping!! News leak??

if this holds above the resistance, uptrend incoming !

thought we were expecting results by the summer or August. I guess there are still enrolling, anyone has any information about this?

Dr. Lucinda Bateman is the Principal Investigator for a phase 2 randomized placebo-controlled #clinicaltrial of valacyclovir plus celecoxib for the treatment of #LongCOVID.
🧪This trial needs to enroll an additional 10 women with #LongCOVID to participate. Link in comments. pic.twitter.com/AyG850tCxR— Bateman Horne Center (@BatemanHorne) July 3, 2024

Has been nice 50% gains…

This will go back into the toilet, then RS. The promo pump fest on stocktwits is over. No worries I've got plenty of shares of this garbage like you all.

I’m pretty sure we can do much better than $1😎 VIRI LONG💰

great!

TEAM VIRI getting noticed😎💰

Virios is pleased that Maxim Group has initiated research coverage with its first research report by analyst Jason McCarthy. Note: Analyst research is conducted independently of the company, and Virios does not endorse or adopt the views expressed in any analyst research report.— Virios Therapeutics (@ViriosBiotech) June 20, 2024

Hi everyone, I like what I heard today, as IMC-2 is being well tolerated by patients, and IMC-1 sounds like it may be attractive for a partnership going into phase 3, and it sounds like we are definitely going to get to $1 without a R/S. This is all just IMO of course, but I’m adding more😎

What they said?

Meeting just ended, and it sure does sound like VIRIOS will be trading above $1 without a reverse split before October 28th😎 VIRI LONG💰

Don’t forget the meeting tomorrow at 1100 folks!! VIRI💰

https://ir.virios.com/

Toute est possible…

Can this regain compliance organically before the deadline of October ?

8-K out. VIRI💰

Nasdaq extension until October 28, 2024.

https://www.sec.gov/ix?doc=/Archives/edgar/data/0001818844/000155837024009066/viri-20240611x8k.htm

VIRI......................https://stockcharts.com/h-sc/ui?s=VIRI&p=W&b=5&g=0&id=p86431144783

Smart this is the demand zone. Kick it into supply zone. 👍

LOL

Buy signal. Reloading.

The chances of that are pretty strong unfortunately.

rest assured it sadly is

hope not a r/s